LSX are known for bringing life science investors together to assess and meet with the most promising up-and-coming biotech companies. When the first mRNA vaccines hit the market in 2020, one of our investors asked us to look at the resurgence of therapeutics targeting or made of RNA with the view to developing a high-level conference. And so, RNA Leaders was born.

Drawing on years of experience from running some of Europe’s most respected life sciences events, we’re excited to bring RNA Leaders to Basel in 2022. The conference will present the most interesting clinical data from biotech and pharma companies developing the next generation of RNA therapies and vaccines.

RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the first annual RNA Leaders World Congress.

So, if you’re passionate about all things RNA do join us, and more than 150 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.